Letters Avastin versus Lucentis

Approve bevacizumab for use in eye disease in cash strapped times

BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e4806 (Published 23 July 2012) Cite this as: BMJ 2012;345:e4806
  1. Ilias Georgalas, consultant ophthalmic surgeon1,
  2. Chrysanthi Koutsandrea, consultant vitreoretinal surgeon1
  1. 1Department of Ophthalmology, University of Athens, 11527 Athens, Greece
  1. igeorgalas{at}yahoo.com

We agree with Godlee that the “miracle” of anti-VEGF (vascular endothelial growth factor) treatment has been overshadowed by the bevacizumab (Avastin) versus ranibuzimab (Lucentis) dispute.1

However, in our opinion, the anti-VEGF treatment versus no treatment debate is even more important. During this economic crisis, many of our patients with …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe